Olapag Tablet 25 mg contains Eltrombopag Olamine, an oral medication used to increase platelet production in patients with low platelet counts (thrombocytopenia). Eltrombopag is a thrombopoietin receptor agonist, which stimulates the bone marrow to produce more platelets, helping prevent bleeding complications associated with low platelet levels.

Olapag is particularly beneficial for patients with conditions such as chronic immune thrombocytopenia (ITP), chronic hepatitis C-associated thrombocytopenia, or aplastic anemia. By enhancing platelet counts, Olapag helps reduce the risk of bleeding, supports safer medical procedures, and improves quality of life in individuals with chronic low platelet conditions.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Olapag Tablet 25 mg is indicated for:

• Chronic immune thrombocytopenia (ITP): To increase platelet count in adults and children with persistent low platelets.

• Thrombocytopenia associated with chronic hepatitis C virus (HCV) infection: To enable initiation and continuation of antiviral therapy.

• Severe aplastic anemia: Used in combination with immunosuppressive therapy to improve platelet levels.

• Other conditions associated with low platelet counts, as advised by a healthcare provider.

This medication is used under the supervision of a hematologist or physician experienced in managing thrombocytopenia.

Key Benefits

• Increases platelet count: Reduces risk of bleeding and bruising in patients with low platelets.

• Supports safe treatment: Helps patients safely undergo surgeries or antiviral therapies that may affect platelet levels.

• Improves quality of life: Reduces the physical and psychological impact of thrombocytopenia.

• Oral administration: Convenient tablet form ensures ease of use and consistent dosing.

• Clinically proven: Eltrombopag is widely studied and recognized for its efficacy in managing chronic low platelet conditions.

Olapag Tablet provides effective management for patients at risk of bleeding due to chronic thrombocytopenia.

Dosage and Administration

• The typical starting dose is 25 mg once daily, taken orally, preferably on an empty stomach (at least 1 hour before or 2 hours after meals, especially those containing calcium).

• Dosage may be adjusted based on platelet response, typically monitored through regular blood tests.

• Maximum daily dose and duration of therapy depend on the condition being treated and the patient’s response.

• Swallow the tablet whole with water; do not crush, chew, or split the tablet unless instructed by a physician.

Consistent adherence to prescribed dosing and monitoring is crucial for safety and effectiveness.

Precautions

• Use with caution in patients with liver disease or renal impairment; dose adjustment may be necessary.

• Monitor platelet counts regularly to avoid excessive platelet elevation, which may increase the risk of blood clots.

• Inform your doctor of any history of thromboembolic events, bleeding disorders, or other chronic conditions.

• Avoid taking supplements containing calcium, iron, magnesium, or aluminum within 2 hours of Olapag, as they can reduce absorption.

• Not recommended during pregnancy or breastfeeding unless prescribed and supervised by a physician.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Olapag Tablet 25 mg is generally well tolerated. Possible side effects include:

• Headache

• Nausea or vomiting

• Fatigue

• Abdominal discomfort or indigestion

• Muscle or joint pain

Rare but serious side effects may include liver function abnormalities, blood clot formation, or severe allergic reactions. Immediate medical attention is required if serious symptoms occur.

Storage Instructions

• Store below 25°C in a cool, dry place.

• Protect from moisture and direct sunlight.

• Keep out of reach of children.

• Do not use after the expiration date printed on the packaging.

Olapag Tablet 25 mg (Eltrombopag Olamine) is an effective and convenient oral therapy for managing thrombocytopenia. It increases platelet counts, reduces bleeding risk, and supports overall quality of life for patients with chronic low platelet conditions.